Cargando…

Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations

According to the cancer burden report released by the International Agency for Research on Cancer (IARC) in 2020, the mortality rate of lung cancer is 18%, ranking first in the world, and its morbidity and mortality rates are highest in China. Pneumonectomy is the preferred treatment for lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yutong, Yuan, Zhenwei, Han, Yuqiang, Zhang, Yanfang, Xu, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149010/
https://www.ncbi.nlm.nih.gov/pubmed/35652105
http://dx.doi.org/10.1016/j.apjon.2022.03.006
_version_ 1784717129215377408
author Lu, Yutong
Yuan, Zhenwei
Han, Yuqiang
Zhang, Yanfang
Xu, Renhua
author_facet Lu, Yutong
Yuan, Zhenwei
Han, Yuqiang
Zhang, Yanfang
Xu, Renhua
author_sort Lu, Yutong
collection PubMed
description According to the cancer burden report released by the International Agency for Research on Cancer (IARC) in 2020, the mortality rate of lung cancer is 18%, ranking first in the world, and its morbidity and mortality rates are highest in China. Pneumonectomy is the preferred treatment for lung cancer patients, but surgery carries a significant risk of perioperative complications, which may affect the patient's functional recovery and quality of life. So, the rehabilitation of the large number of lung cancer patients in China requires greater attention. A number of studies have shown that the enhanced recovery after surgery (ERAS) protocol can reduce the risk of death, readmission rate, adjuvant chemotherapy time, postoperative pain level, anesthesia medication amount, length of stay, and hospitalization expenses. Foreign literature has successively issued guidelines to improve recovery among lung cancer patients, but Chinese-specific literature for patients undergoing lung cancer surgery or thoracic surgery remains inadequate. Some Chinese expert consensus have only considered part of the content of ERAS in thoracic surgery. To summary the evidence of the ERAS program for lung cancer surgery patients at home and abroad basing on evidence-based medicine is necessary. Therefore, this study used evidence-based practical thinking as a guide to (1) evaluate, integrate, and summarize relevant evidence guidelines and data resources at home and abroad so as to construct an enhanced recovery program for lung cancer patients suitable for Chinese national conditions and (2) provide a scientific basis for future research and practice in related fields.
format Online
Article
Text
id pubmed-9149010
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91490102022-05-31 Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations Lu, Yutong Yuan, Zhenwei Han, Yuqiang Zhang, Yanfang Xu, Renhua Asia Pac J Oncol Nurs Review According to the cancer burden report released by the International Agency for Research on Cancer (IARC) in 2020, the mortality rate of lung cancer is 18%, ranking first in the world, and its morbidity and mortality rates are highest in China. Pneumonectomy is the preferred treatment for lung cancer patients, but surgery carries a significant risk of perioperative complications, which may affect the patient's functional recovery and quality of life. So, the rehabilitation of the large number of lung cancer patients in China requires greater attention. A number of studies have shown that the enhanced recovery after surgery (ERAS) protocol can reduce the risk of death, readmission rate, adjuvant chemotherapy time, postoperative pain level, anesthesia medication amount, length of stay, and hospitalization expenses. Foreign literature has successively issued guidelines to improve recovery among lung cancer patients, but Chinese-specific literature for patients undergoing lung cancer surgery or thoracic surgery remains inadequate. Some Chinese expert consensus have only considered part of the content of ERAS in thoracic surgery. To summary the evidence of the ERAS program for lung cancer surgery patients at home and abroad basing on evidence-based medicine is necessary. Therefore, this study used evidence-based practical thinking as a guide to (1) evaluate, integrate, and summarize relevant evidence guidelines and data resources at home and abroad so as to construct an enhanced recovery program for lung cancer patients suitable for Chinese national conditions and (2) provide a scientific basis for future research and practice in related fields. Elsevier 2022-03-26 /pmc/articles/PMC9149010/ /pubmed/35652105 http://dx.doi.org/10.1016/j.apjon.2022.03.006 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Lu, Yutong
Yuan, Zhenwei
Han, Yuqiang
Zhang, Yanfang
Xu, Renhua
Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations
title Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations
title_full Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations
title_fullStr Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations
title_full_unstemmed Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations
title_short Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations
title_sort summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149010/
https://www.ncbi.nlm.nih.gov/pubmed/35652105
http://dx.doi.org/10.1016/j.apjon.2022.03.006
work_keys_str_mv AT luyutong summaryofbestevidenceforenhancedrecoveryaftersurgeryforpatientsundergoinglungcanceroperations
AT yuanzhenwei summaryofbestevidenceforenhancedrecoveryaftersurgeryforpatientsundergoinglungcanceroperations
AT hanyuqiang summaryofbestevidenceforenhancedrecoveryaftersurgeryforpatientsundergoinglungcanceroperations
AT zhangyanfang summaryofbestevidenceforenhancedrecoveryaftersurgeryforpatientsundergoinglungcanceroperations
AT xurenhua summaryofbestevidenceforenhancedrecoveryaftersurgeryforpatientsundergoinglungcanceroperations